In vitro diagnostics and theranostics firm Theradiag said its partner Miraca Life Sciences will start marketing an eighth therapeutic drug monitoring test from Theradiag's Lisa Tracker range in the US.
Under a technology licensing agreement, Miraca will market the test, starting early in November, under the name InformTx.
Theradiag noted that an InformTx report provides clinicians with quantitative test results, historical test result data, and guidance from the most up-to-date peer-reviewed scientific literature. Testing measures the level of a specified drug as well as patient-derived antibodies to the specified drug. Miraca Life Sciences uses laboratory-validated ELISA technology for InformTx therapeutic drug monitoring, and test results are reported within five days.